LOS GATOS, CA - Tenon Medical, Inc., a medical devices company, has been notified by The Nasdaq Stock Market that it currently does not meet the minimum publicly held shares requirement for continued listing. The notification, received on Monday, follows a 1-for-8 reverse stock split executed by the company on the previous Thursday, which reduced its outstanding shares to 510,221, with 490,364 shares deemed publicly held.
The Nasdaq Listing Rule 5550(a)(4) stipulates a minimum of 500,000 publicly held shares. As a result of falling short, Nasdaq has granted Tenon Medical until October 24, 2024, to submit a plan to address the shortfall and regain compliance.
In response, Tenon Medical anticipates resolving the issue by September through a public offering of its common stock, as detailed in a Registration Statement on Form S-1 filed on August 14, 2024. The company's common stock and warrants, traded under the symbols NASDAQ:TNON and NASDAQ:TNONW respectively, will continue to be listed on The Nasdaq Capital Market pending resolution.
This development is based on a press release statement and has no immediate impact on Tenon Medical's listing status, allowing the company time to implement its compliance plan.
In other recent news, Tenon Medical, Inc. revealed significant developments. The company has entered into a Securities Purchase Agreement for a private placement offering, selling shares of its Series B Preferred Stock and warrants, totaling an aggregate offering price of $550,000. Tenon Medical's Series B Preferred Stock is convertible into common stock at the holder's discretion and comes with certain conditions and protections for the investors.
Tenon Medical has also released promising interim results from its MAINSAIL study, suggesting that the Catamaran SI Joint Fusion System may offer significant improvements for patients with sacroiliac joint disorders. The study revealed a marked decrease in pain and disability, a strong safety profile, and high patient satisfaction.
The company has announced the appointment of Kevin Williamson as the new Chief Financial Officer, succeeding Steve Van Dick. Williamson's extensive experience from his previous role as CFO at Accelus Inc. is expected to be beneficial as Tenon Medical advances into its next growth phase.
During the 2024 Annual Stockholders Meeting, shareholders approved key proposals, including the election of seven nominees to the Board of Directors, amendments to the company's equity plan, and the ratification of Haskell & White LLP as the independent auditor for the fiscal year ending December 31, 2024.
The terms of the company's Series B Preferred Stock, related warrants, and an amendment to decrease the conversion price of the Series A Preferred Stock were also approved to comply with Nasdaq Listing Rule 5635(d).
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.